• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[添加速尿至腹膜透析液对透析液和尿液中羟脯氨酸排泄的影响]

[Effect of furosemide added to peritoneal dialysis fluid on hydroxyproline excretion in dialysate and urine].

作者信息

Sucharzewska-Tomczak M, Grzegorzewska A

机构信息

Kliniki Nefrologii Akademii Medycznej im. Karola Marcinkowskiego w Poznaniu.

出版信息

Przegl Lek. 1994;51(7):300-2.

PMID:7871203
Abstract

The effect of furosemide (1500 mg/21 of peritoneal dialysis fluid) on excretion of hydroxyproline in dialysate and its renal clearance was investigated in 12 patients with end-stage renal disease on regular dialysis treatment. The 37 +/- 8% and 20 +/- 6% increase of D/S ratio of hydroxyproline after 5 and 8 hours of dwell, respectively, and 52 +/- 24% increase of renal clearance of hydroxyproline were induced by furosemide, which indicate its significant influence on peritoneal and renal removal of hydroxyproline.

摘要

在12例接受定期透析治疗的终末期肾病患者中,研究了呋塞米(1500毫克/21份腹膜透析液)对透析液中羟脯氨酸排泄及其肾脏清除率的影响。呋塞米分别使羟脯氨酸在留置5小时和8小时后的D/S比值增加37±8%和20±6%,并使羟脯氨酸的肾脏清除率增加52±24%,这表明其对腹膜和肾脏清除羟脯氨酸有显著影响。

相似文献

1
[Effect of furosemide added to peritoneal dialysis fluid on hydroxyproline excretion in dialysate and urine].[添加速尿至腹膜透析液对透析液和尿液中羟脯氨酸排泄的影响]
Przegl Lek. 1994;51(7):300-2.
2
Effectiveness of furosemide in patients on peritoneal dialysis.速尿对腹膜透析患者的疗效。
CANNT J. 2006 Jul-Sep;16(3):40-4.
3
[Estimation of hearing in patients with end stage renal failure being peritoneally dialyzed with and without furosemide in the dialysis fluid].[对接受腹膜透析的终末期肾衰竭患者在透析液中使用和不使用速尿时听力的评估]
Pol Tyg Lek. 1992;47(49-50):1087-9.
4
[Levels of plasma proteins in patients with ene stage renal failure treated with peritoneal dialysis with an addition of furosemide to dialysis fluid].[在透析液中添加呋塞米进行腹膜透析治疗的终末期肾衰竭患者的血浆蛋白水平]
Pol Tyg Lek. 1994;49(6-7):137-40.
5
[Influencing factors in the control of phosphorus in peritoneal dialysis. Therapeutic options].[腹膜透析中磷控制的影响因素。治疗选择]
Nefrologia. 2000 Jul-Aug;20(4):355-61.
6
Relationship between dialysate oxidized protein and peritoneal membrane transport properties in patients on peritoneal dialysis.腹膜透析患者透析液氧化蛋白与腹膜转运特性的关系
Nephrol Dial Transplant. 2008 Oct;23(10):3295-301. doi: 10.1093/ndt/gfn221. Epub 2008 Apr 28.
7
Optimal exchange volume and dialysate flow rate in peritoneal dialysis. A clinical study.腹膜透析中的最佳交换量和透析液流速:一项临床研究
J Assoc Physicians India. 1989 Dec;37(12):762-4.
8
Peroxidase activity in peritoneal neutrophils of patients with terminal renal failure treated by intermittent peritoneal dialysis.接受间歇性腹膜透析治疗的终末期肾衰竭患者腹膜中性粒细胞中的过氧化物酶活性
Med Interne. 1990 Apr-Jun;28(2):135-8.
9
[Effect of intraperitoneal furosemide administration on levels of +proteins+ in plasma and signs of their ability to be dialyzed during intermittent peritoneal dialysis].[腹腔注射速尿对间歇性腹膜透析期间血浆中蛋白质水平及其可透析能力指标的影响]
Pol Tyg Lek. 1991;46(4-5):67-70.
10
[Composition of amino acid in blood and dialysate by patients with in chronic renal insufficiency by peritoneal dialysis].[腹膜透析慢性肾功能不全患者血液和透析液中的氨基酸组成]
Vopr Pitan. 2008;77(3):45-8.